Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Icatibant, sold under the brand name Firazyr, is a medication for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase-inhibitor deficiency. It is not effective in angioedema caused by medication from the ACE inhibitor class.
Read the full article on WikipediaAnticipated emergency treatment of an acute attack of hereditary angioedema Clinical criteria: Treatment Phase: Initial Patient must have confirmed diagnosis of C1-esterase inhibitor deficiency, AND Patient must have been assessed to be at significant risk of an acute attack of hereditary angioedema, AND The condition must be assessed by a clinical immunologist; OR The condition must be assessed by a respiratory physician; OR The condition must be assessed by a specialist allergist; OR The condition must be assessed by a general physician experienced in the management of patients with hereditary angioedema. The name of the specialist consulted must be provided at the time of application for initial supply. The date of the pathology report and name of the Approved Pathology Authority must be provided at the time of application. Increased maximum quantities will be limited to 12 injections per authority prescription.
“Bradykinin is a peptide-based hormone that is formed locally in tissues, very often in response to a trauma. It increases vessel permeability, dilates blood vessels and causes smooth muscle cells to contract. Bradykinin plays an important role as the mediator of pain. Surplus bradykinin is responsible for the typical symptoms of inflammation, such as swelling, redness, overheating and pain. These symptoms are mediated by activation of bradykinin B2 receptors. Icatibant acts as a bradykinin inhibitor by blocking the binding of native bradykinin to the bradykinin B2 receptor. Little is known about the effects of icatibant on the bradykinin B1 receptor.”
Working under the parallel aged-care framework? Aged-care equivalent →